A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

Akkooi, A.C.J. van; Haferkamp, Sebastian; Papa, Sophie; Franke, Viola; Pinter, Andreas; Weishaupt, Carsten; Huber, Margit A.; Loquai, Carmen; Richtig, Erika; Gokani, Priya; Ӧhrling, Katarina; Louie, Karly S.; Mohr, Peter

doi:10.1007/s12325-020-01590-w

Cited by 14 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that T-VEC may be an important consideration for older patients with melanoma who may not be able to tolerate other systemic options. Overall, the real-world data suggests that objective responses and safety profile for T-VEC in melanoma patients are comparable to those observed in the OPTiM phase III clinical trials (van Akkooi et al, 2021). Clinical benefit may be especially high in older patients and in those receiving T-VEC as firstline treatment.…”

Section: Real World Experience With T-vecmentioning

confidence: 61%

“…This has been described as an "abscopal" or "anamnestic" response (Andtbacka et al, 2016a). Animal models have confirmed that injection of an index tumor can cause regression of uninjected tumors in an immune-dependent manner (Zamarin et al, 2014). Thus, OVs provide two independent mechanisms that can reinforce tumor-specific immune clearance.…”

Section: Introductionmentioning

confidence: 89%

“…Because several other promising agents were available, many patients were considered for T-VEC only after having progressive disease after other treatments. Over the last 5 years, however, there has been considerable real-world data published providing a better idea of how best to integrate T-VEC treatment into the clinical practice and how to optimize patient selection and management ( Perez et al, 2018 ; Louie et al, 2019 ; Mohr et al, 2019 ; Perez et al, 2019 ; Louie et al, 2020 ; Sun et al, 2020 ; Kleemann et al, 2021 ; van Akkooi et al, 2021 ). In addition, techniques for injecting T-VEC have now been well established ( Figure 1 ).…”

Section: Real World Experience With T-vecmentioning

confidence: 99%

See 2 more Smart Citations

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class

Kaufman

Shalhout

Iodice

2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Talimogene laherparepvec (T-VEC) is a modified oncolytic herpes Simplex virus, type 1 (HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF). T-VEC is adapted for selective replication in melanoma cells and GM-CSF was expressed to augment host anti-tumor immunity. T-VEC is indicated for the local treatment of melanoma recurrent after primary surgery and is the first-in-class oncolytic virus to achieve approval by the FDA in 2015. This review will describe the progress made in advancing T-VEC to the most appropriate melanoma patients, expansion to patients with non-melanoma cancers and clinical trial results of T-VEC combination studies. Further, strategies to identify predictive biomarkers of therapeutic response to T-VEC will be discussed. Finally, a brief outline of high-priority future directions for investigation of T-VEC and other promising oncolytic viruses will set the stage for a best-in-class oncolytic virus to bring the maximum benefit of this emerging class of anti-cancer agents to patients with cancer.

show abstract

Section: Real World Experience With T-vecmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 89%

Section: Real World Experience With T-vecmentioning

confidence: 99%

See 1 more Smart Citation

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class

Kaufman

Shalhout

Iodice

2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…The use of T-VEC in advanced melanoma is also being evaluated in combination therapy approaches, e.g. together with ipilimumab and pembrolizumab (194,195), with the aim of increased efficacy in patients with visceral metastases. Other vaccine therapies, including dendritic cell-based, peptide-based and vector-based vaccines are also in the testing phase and so far, the results have not been assuring (196).…”

Section: Therapeutic Approaches In Melanomamentioning

confidence: 99%

The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma

et al. 2022

View full text Add to dashboard Cite

The incidence of cutaneous melanoma is rapidly increasing worldwide. Cutaneous melanoma is an aggressive type of skin cancer, which originates from malignant transformation of pigment producing melanocytes. The main risk factor for melanoma is ultraviolet (UV) radiation, and thus it often arises from highly sun-exposed skin areas and is characterized by a high mutational burden. In addition to melanoma-associated mutations such as BRAF, NRAS, PTEN and cell cycle regulators, the expansion of melanoma is affected by the extracellular matrix surrounding the tumor together with immune cells. In the early phases of the disease, hyaluronan is the major matrix component in cutaneous melanoma microenvironment. It is a high-molecular weight polysaccharide involved in several physiological and pathological processes. Hyaluronan is involved in the inflammatory reactions associated with UV radiation but its role in melanomagenesis is still unclear. Although abundant hyaluronan surrounds epidermal and dermal cells in normal skin and benign nevi, its content is further elevated in dysplastic lesions and local tumors. At this stage hyaluronan matrix may act as a protective barrier against melanoma progression, or alternatively against immune cell attack. While in advanced melanoma, the content of hyaluronan decreases due to altered synthesis and degradation, and this correlates with poor prognosis. This review focuses on hyaluronan matrix in cutaneous melanoma and how the changes in hyaluronan metabolism affect the progression of melanoma.

show abstract

“…In addition to T-VEC, non-neurovirulent rhinovirus:poliovirus chimera (PVSRIPO) has been described for treatment-refractory melanoma in a phase I clinical trial showing promising antitumor activity [66]. However, to date, the majority of data regarding virotherapy and melanoma treatment are limited to T-VEC, likely because this is the only FDA-approved oncolytic virus for the treatment of melanoma [67][68][69][70].…”

Section: Virotherapy and Melanomamentioning

confidence: 99%

Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?

et al. 2021

View full text Add to dashboard Cite

Introduction: Melanoma brain metastases remain a devastating disease process with poor prognosis. Recently, there has been a surge in studies demonstrating the efficacy of oncolytic virotherapy for brain tumor treatment. Given their specificity and amenability to genetic modification, the authors explore the possible role of oncolytic virotherapy as a potential treatment option for patients with melanoma brain metastases. Methods: A comprehensive literature review including both preclinical and clinical evidence of oncolytic virotherapy for the treatment of melanoma brain metastasis was performed. Results: Oncolytic virotherapy, specifically T-VEC (Imlygic™), was approved for the treatment of melanoma in 2015. Recent clinical trials demonstrate promising anti-tumor changes in patients who have received T-VEC; however, there is little evidence for its use in metastatic brain disease based on the existing literature. To date, only two single cases utilizing virotherapy in patients with metastatic brain melanoma have been reported, specifically in patients with treatment refractory disease. Currently, there is not sufficient data to support the use of T-VEC or other viruses for intracranial metastatic melanoma. In developing a virotherapy treatment paradigm for melanoma brain metastases, several factors must be considered, including route of administration, need to bypass the blood–brain barrier, viral tumor infectivity, and risk of adverse events. Conclusions: Evidence for oncolytic virotherapy treatment of melanoma is limited primarily to T-VEC, with a noticeable paucity of data in the literature with respect to brain tumor metastasis. Given the promising findings of virotherapy for other brain tumor types, oncolytic virotherapy has great potential to offer benefits to patients afflicted with melanoma brain metastases and warrants further investigation.

show abstract

A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

Cited by 14 publications

References 20 publications

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class

The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma

Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?

Contact Info

Product

Resources

About